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Abstract: Baclofen, an agonist at the B subunit of gaba-aminobutyric acid receptor, possesses
pharmacologic properties that may confer utility for the treatment of alcohol dependence.
Research suggests that not only can it be useful in promoting maintenance of alcohol abstinence
but also it may play a key role in decreasing alcohol cravings and anxiety often associated with
alcohol dependence. To assess the benefit of baclofen for alcohol dependence, a review of the
literature was conducted to identify published data investigating this off-label treatment. Four
randomized controlled trials to date have been published and were included in this review.
Although primary outcomes differ between studies, patients randomized to baclofen experience
higher rates of abstinence from alcohol than those taking placebo in two of the trials. Secondary
analyses indicate that baclofen is safe in patients with alcohol dependence, including those with
moderate to severe liver cirrhosis, and may provide beneficial anxiolytic effects. Despite some
positive data, the largest available randomized controlled trial failed to find any differences
between baclofen and placebo. In all studies, individuals with severe medical comorbidities,
seizure disorders, and psychiatric disorders were excluded from trials, which may limit external
validity. In summary, there may be beneficial effects from using baclofen for the treatment of
alcohol dependence; however, limited conclusions can be drawn from the small number of
studies currently available for review. Larger well-designed trials are needed to further define
baclofen’s role for the treatment of alcohol dependence.
Keywords: baclofen, alcohol, abstinence, relapse, craving, dependence

Alcohol misuse is one of the world’s leading health risks. Alcohol abuse and dependence are associated with more than 60 disease types and injuries that contribute to
approximately 2.5 million deaths annually.1 An estimated 4.5% of the global burden
of disease and injury is attributed to alcohol. Alcohol is also associated with exorbitant
social costs, such as those related to violence, child neglect/abuse, and absenteeism in
the workplace.1 Therapeutic approaches, including pharmacotherapy, play a pivotal
role in treating patients with alcohol use disorders but are commonly underutilized.2
Since the 1951 approval of disulfiram by the Food and Drug Administration (FDA),
three additional treatments have been approved for the treatment of alcohol dependence:
acamprosate, oral naltrexone, and intramuscular naltrexone.3
Despite mixed data from well-designed trials of disulfiram, acamprosate, or
naltrexone, two recent Cochrane reviews concluded that acamprosate and naltrexone appear to be safe and effective in patients with alcohol dependence, with
moderate effect sizes.4–8 However, due to various barriers to the use of acamprosate,
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n altrexone, or disulfiram, some patients are unable to take
these FDA-approved agents. Acamprosate is contraindicated
in patients with severe renal impairment (ie, estimated creatinine clearance [CrCl] ,30 mL/min), and gastrointestinal
adverse events may prevent use or limit dose maximization.
Naltrexone is contraindicated in patients with acute hepatitis or hepatic failure and may not be used in patients with
concomitant opioid utilization. Disulfiram must be used
with caution in multiple disease states, such as diabetes
mellitus, hypothyroidism, and seizures; patients must also be
warned not to consume “hidden” alcohol, such as tonics and
mouthwashes, in order to avoid unintended toxic effects of
the medication. Nonadherence with oral naltrexone remains
a barrier to effective treatment for a large portion of patients,
so intramuscular naltrexone has been developed for oncemonthly administration and has additional advantages of
steady therapeutic drug concentration and decreased peak
and trough effects.9
The off-label use of multiple medications, including
baclofen, has been investigated for maintenance of abstinence
from alcohol. Baclofen was originally approved by the FDA
in 1977 for use in spasticity associated with neurologic conditions, such as multiple sclerosis and spinal cord lesions.10
Baclofen’s pharmacologic properties have led to investigation of its benefit for the treatment of alcohol dependence.

Baclofen: pharmacokinetics
and pharmacodynamics
Baclofen is an agonist at the B subunit of gaba-aminobutyric
acid receptor (GABAB). GABAB receptors are metabotropic
and differ from the ionotropic GABAA and GABAC receptors.
GABAB receptors are highly expressed in the limbic system,
suggesting a major role in regulating emotional behavior.
GABA neurotransmission is also known to be an important
factor in the control of anxiety. Following these lines of evidence, activation of GABAB receptors might reduce anxiety.11
Noting that anxiety is a common symptom in patients being
treated for alcohol withdrawal and alcohol dependence, activating GABAB receptors might be useful in the treatment of
alcohol withdrawal and dependence.
Mesolimbic dopamine neurons, found in the same areas of
the brain as GABAB receptors, are thought to be involved in
the mediation of alcohol intake and reinforcement. Activation
of GABAB receptors by baclofen may result in local inhibition
of surrounding dopamine neurons. Through this mechanism,
alcohol-stimulated dopamine release would be reduced,
thereby decreasing positive reinforcement from alcohol
consumption and aiding in abstinence from alcohol.12
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Despite high individual variation in pharmacokinetics,
baclofen is rapidly and extensively absorbed from the gastrointestinal tract following oral administration, though there
is some suggestion that absorption is inversely related to
dose.13,14 Peak plasma concentrations are generally observed
2–3 hours after ingestion. Baclofen’s elimination half-life is
2–6 hours and it is usually dosed three to four times daily.13
Baclofen is excreted primarily unchanged by the kidneys,
making it a useful agent in patients with impaired hepatic
function or a high potential for hepatic cytochrome P450mediated drug-drug interactions.

Evidence for baclofen
in maintenance of alcohol
dependence: a critical evaluation
Numerous case reports, case series, and open-label trials
have been published evaluating baclofen for the treatment
of alcohol dependence; most of the primary outcomes focus
on abstinence from alcohol (Table 1.) Limited data are available from well-conducted trials, though numerous trials are
underway or recently completed with a goal of evaluating
baclofen for maintenance of abstinence in alcohol-dependent
patients.15 A search of MedLine (1966–2013) using the terms
“baclofen,” “alcohol,” “abstinence,” “relapse,” “craving,” and
“dependence” was conducted to identify English language
articles. Randomized controlled trials (RCTs) are evaluated
in the following text and summarized in Table 2.
Addolorato et al16 conducted an RCT evaluating the
effectiveness and safety of baclofen for maintenance of
alcohol abstinence specifically in patients with cirrhosis
of the liver. All subjects had a biopsy-proven diagnosis of
cirrhosis; their alcohol intake included at least two heavy
drinking days per week, with an average of at least 21 drinks
weekly for men and 14 drinks weekly for women. Exclusion
criteria included the presence of severe cardiac or pulmonary
disease. Individuals with other addictions (except nicotine),
pharmacologically treated psychiatric diagnoses, epilepsy,
a severe medical illness, renal dysfunction, or the use of interferon or corticosteroids within 60 days of enrolment were also
excluded. Subjects were initially hospitalized for 3–4 days
to complete a medical evaluation and treatment for alcohol
withdrawal syndrome (AWS) with diazepam. After resolution
of AWS, subjects were eligible for randomization. Eightyfour subjects with a median age of 56 years (interquartile
range 45.5–62 years) were included in this study. The active
treatment group received baclofen 10 mg orally three times
daily. Assessments and counseling sessions occurred weekly
for 4 weeks and then biweekly for the remainder of the
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OL

CR

CR

CR

CS

OL

CS

OB, R

Addolorato
et al35

Agabio
et al26

Ameisen36

Bucknam37

Dore
et al22

Flannery
et al38

Pastor
et al39

Rigal et al40

132 (63% male, 37% female;
mean age 47 ± 11 y)

4 (3 male, 1 female;
age range 31–46 y)

12 (9 male, 3 female;
mean age 42 ± 7 y)

13 (10 male, 3 female;
mean 49 y with range
41–62 y)

1 (male, 59 y)

1 (male, 50 y)

1 (male, 48 y)

9 (all males; mean age
44 +/-10.1)

Patients

1 year of
follow-up

7–9 months
of follow-up
during
abstinence

12 weeks

Follow-up
ranged from
4 days to
27 months

Not specified,
was at least
1 month

9 months

48 weeks

4 weeks

Length
of treatment

Maximum dose
145 ± 75 mg/day
and average dose at 1 year
of 129 ± 71 mg/day

75–125 mg/day

5 mg tid × 3 days,
then 10 mg tid

30–275 mg/day tid

10 mg tid, adding 20 mg/day
every third day; optional
20–40 mg/day prn cravings;
final dosing 120 mg/day
100 mg/day tid; increased
to 140 mg/day tid on
stressful days

Decreased amount drank; if patient chose to
drink, it was limited to 12 drinks/week,
or 3 drinks/occasion; previous consumption
was 35 drinks/week, or 12 drinks/occasion
Five patients had 0 drinking days during follow-up
(7 weeks to 18 months), 2 patients relapsed day
after discharge (noncompliance with baclofen),
6 others relapsed a total of 1–140 days during
their follow-up
Mean number of drinks per drinking day
decreased from 7.6 ± 2.2 to 4.7 ± 3.5; heavy
drinking decreased from 88.3% ± 16.6% of the
days to 55% ± 40% of the days; abstinence
increased from 9.4% ± 10.6% of the time to
31% ± 34.2% of the time
2 patients achieved abstinence and did not
relapse with a dose reduction; 1 patient
experienced increased cravings and relapse
with dose reduction, which resolved with dose
increase; 1 patient relapsed on high-dose baclofen
but was associated with a depressive episode
At year 1, 78 patients remained abstinent,
28 were drinking at or below the “low risk” level,
and 26 were drinking above the “low risk” level

7 maintained abstinence; 2 continued drinking
but substantially decreased weekly drinks during
first week of treatment
Stopped drinking during first week of treatment;
consumed only 1 drink during week 18 of
48 weeks of observed treatment
Remained abstinent from alcohol during
those 9 months

5 mg tid × 3 days,
then 10 mg tid
5 mg tid × 3 days,
then 10 mg tid

Results

Baclofen dosing

Note: *Means reported as standard deviations unless noted otherwise.
Abbreviations: CR, case report; CS, case series; OB, observational; OL, open label; prn, as needed; R, retrospective; tid, three times daily; y, years.

Design

Reference

Table 1 Additional studies/reports evaluating the use of baclofen for alcohol dependence*

At year 1, 83% of patients were
still taking baclofen; 86% of patients
experienced side effects, most
transient and during dose increases

When titrated slowly, there
were few side effects and it was
generally well tolerated

No participant achieved complete
abstinence; during the initial week,
only 2 participants remained
abstinent, and only 1 remained
abstinent until week 8

Generally well tolerated unless at
high doses (120 mg and 275 mg)

Experienced mild relaxation, not
sedation, as side effect

No alcohol cravings or anticipatory
anxiety of relapse

Cravings significantly reduced
during first week of treatment;
tolerability was fair

Other
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Table 2 Description of randomized controlled trials
Source

Addolorato et al16

Garbutt et al18

Addolorato et al19

Setting

Single inpatient site

Outpatients recruited from community

Single inpatient site

84
49.0 (range 43.0–61.0)
76%
Not reported
22.0 (range 17.0–27.0)
Cirrhosis (Child-Pugh A, B, or C)
Baclofen 10 mg po tid for 12 weeks
Percentage of patients maintaining
abstinence: 71% vs 29% (P = 0.0001)
Cumulative abstinent days:
62.8 ± 5.4 vs 30.8 ± 5.5 (P = 0.001)

80
47.5 ± 7.6
55%
7.3 ± 3.7 (baclofen group)
23.5 ± 9.9
No medical/psychiatric
Baclofen 10 mg po tid for 12 weeks
Percentage of heavy drinking days:
19.3% vs 24.7% (P = 0.73)
Percentage of abstinent days:
51.7% vs 51.6% (P = 0.61)

39
45.8 ± 10.6
Not reported
14.2 ± 7.9 (all subjects)
12.6 ± 4.8
No medical/psychiatric
Baclofen 10 mg po tid for 4 weeks
Percentage of patients maintaining
abstinence: 70% vs 21.2% (P , 0.005)
Cumulative abstinent days:
19.6 ± 2.6 vs 6.3 ± 2.4 (P , 0.005)

Subjects
Number
Age (y)
Male gender
Daily drinks
Duration of use (y)
Comorbidities
Intervention
Primary outcome/
results

Note: Reported as mean + standard deviation unless noted otherwise.
Abbreviations: po, orally; tid, three times daily; vs, versus; y, years.

12-week study period. The primary outcome was the effect
of baclofen on total abstinence and cumulative abstinence
duration. Craving level was assessed using a version of the
Obsessive Compulsive Drinking Scale.
A greater proportion of subjects maintained abstinence in
the baclofen group compared with the placebo group (71%
versus [vs] 29%; odds ratio [OR] 6.3 [95% confidence interval (CI) 2.4–16.1]). There was also a greater mean cumulative
days abstinent in the treatment group (62.8 days) versus the
placebo group (30.8 days) (P = 0.001). Survival analysis
demonstrated a lower rate of 60-day relapse with baclofen
treatment as compared with placebo (hazard ratio 0.4 [95% CI
0.2–0.8]). Subjects with Child-Pugh class B and C cirrhosis
assigned to the baclofen group were more likely to abstain
from alcohol altogether than those in the placebo group
(OR 4.5 [95% CI 1.2–17.4] and 8.3 [95% CI 1.7–41.3]),
respectively. No significant difference was observed for
subjects with Child-Pugh class A cirrhosis. Baclofen treatment did result in a statistically significant improvement in
Obsessive Compulsive Drinking Scale scores, suggesting less
craving for alcohol in those on baclofen therapy. Laboratory
values improved among those randomized to baclofen and
were consistent with decreased alcohol use, reflected by
decreased transaminases and improved markers of synthetic
liver function. Baclofen was well tolerated and there were
no life-threatening adverse events reported with baclofen use
(headache, n = 4; vertigo, n = 2; tiredness, n = 1; sleepiness,
n = 1) or with its discontinuation at the end of the treatment
phase.
A post hoc analysis from the same study evaluated only
subjects with a secondary diagnosis of hepatitis C virus
(HCV) infection.17 As with the entire cohort, subjects with
HCV demonstrated a greater likelihood of total alcohol
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a bstinence when taking baclofen (83.3%) versus placebo
(25%); P = 0.01. However, these results should be interpreted
with caution, given the limitations of post hoc analyses, with
additional well-conducted studies needed to confirm the
safety and efficacy in patients with HCV infection.
Based on the data from Addolorato et al,16 baclofen
appears to be a well-tolerated and effective medication for
the promotion of alcohol abstinence in patients with cirrhosis.
It is important to note limitations of the study, however,
including limited ability to generalize the findings to other
patient populations (limited external validity), given the
narrow inclusion and exclusion criteria. In addition to problems with external validity, the study exhibits challenges
related to statistical inference and missing data. For instance,
although various laboratory parameters were reported as
statistically different from group to group, it is difficult to
ascertain clinical significance without information about the
actual laboratory values in the two groups. Additionally, it is
unclear whether bias was introduced due to the use or choice
of benzodiazepine used to treat initial symptoms associated
with AWS. Although a similar number of patients received
treatment with diazepam (13 subjects in the baclofen group
received diazepam vs eleven in the placebo group), the mean
dosage received was not available. Given that diazepam has
a long elimination half-life, which may be additionally prolonged in liver disease, its use may have impacted craving for
alcohol and symptoms of anxiety and irritability traditionally
associated with withdrawal.
Garbutt et al18 conducted a double-blind RCT assessing the efficacy and safety of a total daily dose of 30 mg of
baclofen for alcohol dependence. The primary outcomes of
the study were number of heavy drinking days and proportion of abstinence between groups. Other outcomes included
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percentage abstinent days, time to usage, craving, anxiety,
depression, and safety information. Individuals with a diagnosis of alcohol dependence and at least two heavy drinking
days weekly during the 4 weeks prior to enrolment were
eligible for participation. Those with significant medical
comorbidities, including seizure disorder, psychiatric diagnoses, or abnormal hepatic or renal laboratory values, were
excluded. Concomitant use of insulin, oral antihyperglycemics, anticonvulsants, and psychotropics (except stable
doses of antidepressants) was not permitted. Subjects were
evaluated at baseline and weekly for 4 weeks and then twice
monthly for the remainder of the 12-week study period. They
also received eight psychosocial sessions during the study
time frame. Eighty subjects were included; randomization
was stratified by sex. Of the 44 men, 22 received baclofen
and 22 received placebo. A total of 36 women were included,
and 18 were randomized to baclofen therapy.
In the baclofen group, 25.5% ± 23.6% of days over the
12-week period were described as heavy drinking days; this
was statistically indistinguishable from the 25.9% ± 23.6% of
days described as heavy drinking days in the placebo group
(P = 0.56). There were no differences between groups in
terms of weekly heavy drinking days, percentage abstinent
days, or for the secondary outcomes of craving, depression,
or anxiety. Though the study failed to demonstrate benefit
from the drug, baclofen was well tolerated with no significant reported adverse events. Drowsiness (placebo, n = 4;
baclofen, n = 11) and headache (placebo, n = 4; baclofen,
n = 1) were the most commonly reported events and did not
differ between groups. A limitation in this study relates to
the stringent exclusion criteria, which may have excluded
subjects who could have derived benefit and also limits
generalizability (ie, a threat to external validity). Moreover,
subjects in this study may have been less severely dependent
on alcohol than in the Addolorato study, and baclofen may
have more impact on more dependent individuals.
The two aforementioned trials were conducted in response
to open-label data, and a preliminary 30-day double-blind
RCT conducted by Addolorato et al19 in 2002 at the same
facility from which the 2007 data were obtained. In this trial,
39 subjects with a diagnosis of alcohol dependence were
randomized to receive placebo or baclofen titrated to a total
daily dose of 30 mg by day 4 of the study. To be included in
the study, subjects were required to have consumed alcohol
within 24 hours of enrolment, and they were required to have
a family member available to participate in follow-up visits
and to ensure adherence. Individuals with severe kidney,
liver, or heart disease were excluded, as were those with
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psychopathologic illnesses, addiction to other substances
(except nicotine), and seizure disorders or those using antiepileptic medications. After randomization, subjects could
receive emergent diazepam for symptoms associated with
AWS, though none required this intervention. Subjects were
evaluated weekly for outcomes related to abstinence using
patient self-report and alcohol concentration. Cravings,
biologic markers of alcohol abuse, anxiety, depression,
and adverse events during the trial were also assessed on a
weekly basis.
A greater percentage of subjects in the baclofen group
(70%) achieved and maintained abstinence versus the placebo
group (21.1%, P , 0.005). The cumulative days abstinent
(±standard error of the mean) over the 4-week period was
also greater in the baclofen group, 19.6 ± 2.6 days and
6.3 ± 2.4 days (P , 0.005). Mean number of daily drinks
decreased over the course of 2 weeks from 18 to less than
0.5 in the baclofen group, compared with a decrease from ten
to four in the placebo group. Secondary outcomes of cravings
and anxiety were significantly reduced in those treated with
baclofen as compared with placebo, but scores for depressive
symptoms did not differ between the two groups. No statistical analysis was conducted on biologic markers of hepatic
function; however, both groups had reductions of gammaglutamyl transpeptidase, aspartate aminotransferase, and
alanine transaminase by approximately 50% from baseline.
Baclofen was well tolerated, with no discontinuations for
adverse events. The most commonly reported side effect in
the treatment group was sleepiness (n = 2). The duration of
the trial was short, leading to the evaluation of baclofen in
longer trials with larger sample sizes.
Information regarding a fourth double-blind RCT, which
planned to evaluate the effect of baclofen on the maintenance
of abstinence, has been described.10 However, data are available only from a post hoc analysis in a separate publication,
due to protocol violations and recruitment issues. 20 The
International Baclofen Intervention Study (IBIS) attempted
to recruit subjects from four European countries. Baclofen
60 mg daily, baclofen 30 mg daily, and placebo groups
were compared for the primary outcomes of heavy drinking
days, abstinence days, and alcohol craving. Assessments
were made at weekly intervals for the first 4 weeks and
then decreased to every other week for the remainder of
the 12-week trial. There was also a final follow-up visit at
week 16, 4 weeks after the last dose of baclofen or placebo. At
enrolment, patients were assessed and treated for AWS with
diazepam when necessary. Those requiring AWS treatment
for greater than 10 days were excluded. Brief psychological
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intervention was provided and medication adherence was
assessed at each follow-up assessment.
Due to protocol violations and missing data, authors
excluded 51 subjects from Australian and Austrian study
sites, and a third site in the UK did not enrol any patients.
Primary analysis of the IBIS study data is commented upon
in a second publication20 and reported that no significant
differences were found for primary outcomes but noted that
due to exclusions the study failed to meet power.
In this second publication is also a post hoc analysis of
the 42 Italian subjects meeting the inclusion and exclusion
criteria of the IBIS study. Reported as incidence rate ratios
when compared with placebo, baclofen 30 mg was reported
to have a 53% reduction of daily drinks and baclofen 60 mg
daily a 68% reduction of daily drinks (P , 0.001). The
authors concluded that there was an association between
increasing dose and increasing effect (P = 0.0214). This
study utilized doses higher than those previously studied for
this indication; however, all treatment groups continued to
have minimal adverse events, with headache and sleepiness
those most commonly reported. Due to the small number of
subjects and the post hoc nature, it is difficult to draw firm
conclusions regarding the benefit of 60 mg compared with
30 mg of baclofen for this indication. Further well-conducted
studies are needed to confirm whether higher doses of
baclofen may confirm greater efficacy.

Is baclofen safe for maintenance
of alcohol dependence?
Baclofen has been used safely for decades as an antispasticity medication. Only recently has the understanding of the
pathophysiology of alcohol dependence evolved, leading
to the evaluation of baclofen’s role for the maintenance
of alcohol dependence. Although data are mixed regarding baclofen’s efficacy in alcohol dependence, data are
consistent in terms of safety. The most commonly reported
adverse events include headache, drowsiness, nausea, and
vertigo.11,18–20 In addition to central nervous system effects,
nausea may occur in up to 12% of patients but can be minimized by gradual titration to a target dose or taking baclofen
with food.21 No difference in adverse events between the
30 mg and 60 mg daily dosing has been identified.20 Literature
supporting higher doses of baclofen, mostly case reports and
series, has reported the safe use of doses up to 275 mg daily.22
However, there are very limited safety data utilizing highdose baclofen in alcohol-dependent patients, and significant
adverse events have been reported, including overdose and
seizures.21–23
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Evidence also supports baclofen as a safe maintenance
treatment for alcohol dependence, even when patients continue to consume alcohol or resume drinking alcohol. Evans
and Bisaga24 studied 18 heavy social drinkers who consumed
intoxicating levels of alcohol and demonstrated no adverse
effects from the combination of alcohol and baclofen. Rare
but serious adverse effects associated with baclofen in other
uses, including encephalopathy, seizure, and hyperammonemia, have not been identified in clinical trials investigating
its use for alcohol dependence.11,18–20 No negative sequelae
have been reported with baclofen discontinuation in alcohol
dependence studies, though seizures and other neuropsychiatric symptoms have been reported after abrupt discontinuation
of oral baclofen when used for other indications.21 The lack
of noted adverse events may be a result of small sample sizes
and low doses of baclofen utilized in available trials, and
clinicians should remain mindful of possible rare adverse
events associated with baclofen. However, with available
data suggesting safety, further investigation of baclofen’s
role in the treatment of alcohol dependence is warranted.

Discussion
The evidence supporting the safe and effective use of
baclofen for maintenance treatment of alcohol dependence
is growing, as evidenced by the number of ongoing or
recently completed trials. From the studies reviewed here,
it appears that baclofen may prolong the time to first drink,
reduce overall drinking days, and facilitate maintenance of
abstinence in select populations. Baclofen appears to be well
tolerated at the doses that have been evaluated. The available
evidence suggests a potentially unique impact of baclofen
for the treatment of alcohol dependence, given that it has
been safely used in patients with comorbid cirrhosis of the
liver, a disease that is not uncommon in alcohol-dependent
patients. However, the role of baclofen in patients with other
medical and psychiatric comorbidities remains unclear.
With the exception of stable antidepressant use, those with
a treated comorbid psychiatric illness were excluded from
RCTs. As the efficacy of baclofen has not been conclusively
confirmed for the maintenance of alcohol abstinence, excluding subjects taking other psychotropic medications may avoid
confounding from other psychotropic agents that may have
beneficial effects on alcohol intake. However, baclofen may
provide clinical benefit in those with underlying anxiety,
and expanding future inclusion criteria in clinical trials
would be important to test this hypothesis. Addolorato et al19
found improvements in anxiety but not depression scores
in patients treated with baclofen. The anxiolytic effects of
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baclofen have also been shown to be greater than placebo in
alcoholic patients, producing similar results to both low-dose
amitriptyline and diazepam, though in that particular study
abstinence from alcohol was not measured or reported.25
One case report describes a patient with schizophrenia and
alcohol dependence who experienced decreased alcohol
intake and cravings when he was treated with baclofen.26
Additionally, Dore et al22 reported a case series of baclofen
use in dually diagnosed individuals (n = 13). When doses
ranging from 30 mg to 275 mg of baclofen were used daily,
eight (61.5%) subjects experienced a significant abstinence
period or reduction in drinking quantity. Four subjects also
reported beneficial anxiolytic effects. Unfortunately, two
subjects overdosed with baclofen, and seven patients experienced mild to moderate adverse events, including drowsiness,
nocturnal enuresis, forgetfulness, and dizziness. Additional
data supporting the efficacy and safety of baclofen in dually
diagnosed patients are warranted and necessary before it can
be firmly recommended over other potential options.
RCTs of baclofen for the maintenance of alcohol
abstinence also excluded patients with documented seizure disorders. However, it is unclear whether individuals
with alcohol-related seizures were also excluded. It has
been estimated that at least 15% of patients with alcohol
dependence have a documented seizure history. Alcohol
itself is a significant risk factor for the development of
status epilepticus.27 Though prospective trials of baclofen
for alcohol dependence have not demonstrated increased
seizure risk, the package insert and other trials report a risk
of baclofen-related seizures at doses greater than 200 mg per
day.13,28 Albeit a rare event, the association of seizures with
baclofen withdrawal and overdose should bring awareness
for the potential for seizure-related complications. This fact
was highlighted in one case report describing a patient with
no seizure history who developed two seizures while being
treated with baclofen 240 mg daily for the maintenance of
alcohol abstinence.23
An additional population excluded in the trials discussed
was those with renal dysfunction. Renal impairment can
lead to the accumulation of baclofen, resulting in increased
adverse events. Currently, there are no manufacturer recommendations for renal dose adjustments for baclofen. There are
also limited data on baclofen toxicity in patients with varying
degrees of renal impairment. El-Husseini et al14 proposed that
baclofen not be given to those with CrCl ,30 mL/min and
be initiated and titrated slowly when CrCl is 30–50 mL/min.
It has also been suggested to use caution in patients with
subclinical or mild renal impairment, as serum concentration
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of stable baclofen doses has been observed to increase over
time.29
Given the limited external validity and methodological
limitations of current literature, clinicians should be aware of
other medications studied off label for maintenance of alcohol
abstinence. Although an extensive review of such agents is
beyond the scope of this article, medications that have been
studied include antiepileptic agents. Topiramate, gabapentin,
and pregabalin have also been studied in RCTs and have
demonstrated benefits for decreasing the percentage of heavy
drinking days, percentage of days abstinent from alcohol, and
number of drinks per day.2,30,31 These medications have the
advantages of increasing the seizure threshold and having specific FDA-approved renal dosing recommendations for patients
with renal impairment. Gabapentin and pregabalin have also
been shown to have beneficial effects on anxiety. Limitations
to the use of these agents include adverse cognitive effects that
may limit topiramate titration to an optimal dose, and the rare
occurrence of euphoria associated with pregabalin.
Other medications, such as quetiapine, a second-generation
antipsychotic, have been specifically studied in dual-diagnosed
patients (psychiatric disorder and alcohol dependence) and
may confer decreased alcohol consumption and cravings.32
Quetiapine has also been studied for bipolar disorder,
depression, generalized anxiety disorder, and schizophrenia.
Available data are mixed, but quetiapine may be a consideration in alcohol-dependent patients with a comorbid psychiatric diagnosis, with its effect, in part, from promoting stability
of the co-occurring psychiatric diagnosis.32–34

Conclusion
Currently published literature involving baclofen for the
maintenance of alcohol abstinence is limited and difficult
to apply to many patient populations. However, trials
are currently ongoing, and the role of baclofen should become
clearer as results are made known. Clinicians should be aware
of both the risks and benefits associated with baclofen and its
selection over other second-line agents. Selection of an agent
for this indication should be based on patient characteristics,
including organ function and comorbid diseases, specifically
psychiatric illnesses and seizure disorders of any type.
Although the literature is not sufficient to recommend
baclofen as a first-line agent for the treatment of alcohol
dependence, clinicians should maintain awareness of new and
novel uses of medications for alcohol dependence. Though
data are inconclusive, there is some suggestion that baclofen
30–60 mg daily may be safe and effective for the treatment
of alcohol-dependent individuals with normal renal function,
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with or without advanced liver disease, who have not been
diagnosed with a psychiatric illness and do not carry a history of seizures.
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